BMY Stock Summary and Trading Ideas (Bristol-Myers Squibb Company | NYSE:BMY)

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Bristol-Myers Squibb Company trades on the NYSE stock market under the symbol BMY.

As of June 9, 2026, BMY stock price climbed to $56.48 with 10,146,707 million shares trading.

BMY has a beta of 0.62, meaning it tends to be less sensitive to market movements. BMY has a correlation of 0.09 to the broad based SPY ETF.

BMY has a market cap of $115.32 billion. This is considered a Large Cap stock.

Last quarter Bristol-Myers Squibb Company reported $11 billion in Revenue and $1.58 earnings per share. This beat revenue expectation by $571 million and exceeded earnings estimates by $.15.

In the last 3 years, BMY traded as high as $66.38 and as low as $39.35.

The top ETF exchange traded funds that BMY belongs to (by Net Assets): VTI, VOO, SCHD, IVV, SPY.

BMY has underperformed the market in the last year with a price return of +21.8% while the SPY ETF gained +24.3%. BMY has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -5.3% and -5.0%, respectively, while the SPY returned +9.9% and -1.2%, respectively.

BMY support price is $54.59 and resistance is $56.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMY shares will trade within this expected range on the day.